Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Breast Neoplasms 9Prostatic Neoplasms 8Pancreatic Neoplasms 6Uterine Cervical Neoplasms 4Neoplasms 4Brain Neoplasms 4Triple Negative Breast Neoplasms 3Rectal Neoplasms 3Lymphoma, Non-Hodgkin 3Lymphoma 3Lung Neoplasms 3Liver Neoplasms 3Urinary Bladder Neoplasms 2Stomach Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia 2Hodgkin Disease 2Glioma 2Esophageal Neoplasms 2Disease 2Colonic Neoplasms 2Carcinoma, Neuroendocrine 2Carcinoma, Hepatocellular 2Carcinoma in Situ 2Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Dysplasia 1Thoracic Neoplasms 1Thoracic Diseases 1Spinal Diseases 1

Interventions

fludarabine 52Cyclophosphamide 50venetoclax 48Azacitidine 46fludarabine phosphate 41Whole-Body Irradiation 33Specimen Handling 31Mycophenolic Acid 30Tacrolimus 28Melphalan 28Busulfan 27Cytarabine 25Stem Cell Transplantation 23Decitabine 23Biopsy 22Granulocyte Colony-Stimulating Factor 19Sirolimus 16Peripheral Blood Stem Cell Transplantation 16Filgrastim 16Thiotepa 15decitabine and cedazuridine drug combination 14Injections 14Cyclosporine 13ruxolitinib 9Methotrexate 9Mesna 9Hematopoietic Stem Cell Transplantation 9X-Rays 8Idarubicin 8Daunorubicin 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myelodysplastic Syndromes × Magnetic Resonance Imaging × 1 year × Clear all
NCT02356159 2025-09-30

Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
34 enrolled 18 charts
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡